MedTrace Logo

Respiratory Aerosols in Patients With COVID-19 and Healthy Controls

NCT04739020 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 525

Last updated 2021-12-15

No results posted yet for this study

Summary

The proposed study will investigate respiratory aerosols in SARS-CoV-2 (Severe Acute Respiratory Syndrome Corona Virus 2) positive and negative children and adults with the Resp-Aer-Meter (Palas GmbH). For this purpose, first, the measurement of respiratory aerosols (particle sizes and concentration) with the Resp-Aer-Meter will be established. Thereafter, a comparison between polymerase chain reaction (PCR) SARS-CoV-2 positive and negative participants (children and adults) will be conducted. In addition to the measurement of aerosols, the clinical symptoms, lung function (FEV1) and laboratory inflammatory markers will be analyzed.

Conditions

Interventions

DIAGNOSTIC_TEST

Resp-Aer-Meter

Measurement of respiratory aerosols (particle size and concentration) through breathing into the Resp-Aer-Meter for 3-6 Minutes and comparison between groups.

DIAGNOSTIC_TEST

Spirometry

Comparison of peak expiratory flow (PEF) and forced expiratory volume in one second (FEV1) between groups.

DIAGNOSTIC_TEST

Qualitative and quantitative virus PCR of respiratory secretions in patients with high aerosol concentrations

Comparison between result of aerosol measurement and quantitative and qualitative virus PCR of respiratory secretions that are caught in a filter in which the patient breathes for 10 minutes. Test will be conducted on patients with high aerosol concentrations (\>5000/L).

Sponsors & Collaborators

  • Palas GmbH

    collaborator UNKNOWN

  • Johann Wolfgang Goethe University Hospital

    lead OTHER

Principal Investigators

  • Stefan Zielen, Professor · Johann Wolfgang Goethe University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-18
Primary Completion
2021-12-30
Completion
2021-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04739020 on ClinicalTrials.gov